Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway. 2010

Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
Department of Immunology, Erasmus MC Rotterdam, Rotterdam, The Netherlands.

The adapter protein Slp65 is a key component of the precursor-B (pre-B) cell receptor. Slp65-deficient mice spontaneously develop pre-B cell leukemia, but the mechanism by which Slp65(-/-) pre-B cells become malignant is unknown. Loss of Btk, a Tec-family kinase that cooperates with Slp65 as a tumor suppressor, synergizes with deregulation of the c-Myc oncogene during lymphoma formation. Here, we report that the presence of the immunoglobulin heavy chain transgene V(H)81X prevented tumor development in Btk(-/-)Slp65(-/-) mice. This finding paralleled the reported effect of a human immunoglobulin heavy chain transgene on lymphoma development in Emu-myc mice, expressing transgenic c-Myc. Because activation of c-Myc strongly selects for spontaneous inactivation of the p19(Arf)-Mdm2-p53 tumor suppressor pathway, we investigated whether disruption of this pathway is a common alteration in Slp65(-/-) pre-B cell tumors. We found that combined loss of Slp65 and p53 in mice transformed pre-B cells very efficiently. Aberrations in p19(Arf), Mdm2, or p53 expression were found in all Slp65(-/-) (n = 17) and Btk(-/-)Slp65(-/-) (n = 32) pre-B cell leukemias analyzed. In addition, 9 of 10 p53(-/-)Slp65(-/-) pre-B cell leukemias manifested significant Mdm2 protein expression. These data indicate that malignant transformation of Slp65(-/-) pre-B cells involves disruption of the p19(Arf)-Mdm2-p53 tumor suppressor pathway.

UI MeSH Term Description Entries
D007135 Immunoglobulin Variable Region That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions. Variable Region, Ig,Variable Region, Immunoglobulin,Framework Region, Immunoglobulin,Fv Antibody Fragments,Fv Fragments,Ig Framework Region,Ig Variable Region,Immunoglobulin Framework Region,Immunoglobulin Fv Fragments,Immunoglobulin V,Antibody Fragment, Fv,Antibody Fragments, Fv,Fragment, Fv,Fragment, Fv Antibody,Fragment, Immunoglobulin Fv,Fragments, Fv,Fragments, Fv Antibody,Fragments, Immunoglobulin Fv,Framework Region, Ig,Framework Regions, Ig,Framework Regions, Immunoglobulin,Fv Antibody Fragment,Fv Fragment,Fv Fragment, Immunoglobulin,Fv Fragments, Immunoglobulin,Ig Framework Regions,Ig Variable Regions,Immunoglobulin Framework Regions,Immunoglobulin Fv Fragment,Immunoglobulin Variable Regions,Regions, Immunoglobulin Variable,Variable Regions, Ig,Variable Regions, Immunoglobulin
D007143 Immunoglobulin Heavy Chains The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa. Immunoglobulins, Heavy-Chain,Heavy-Chain Immunoglobulins,Ig Heavy Chains,Immunoglobulin Heavy Chain,Immunoglobulin Heavy Chain Subgroup VH-I,Immunoglobulin Heavy Chain Subgroup VH-III,Heavy Chain Immunoglobulins,Heavy Chain, Immunoglobulin,Heavy Chains, Ig,Heavy Chains, Immunoglobulin,Immunoglobulin Heavy Chain Subgroup VH I,Immunoglobulin Heavy Chain Subgroup VH III,Immunoglobulins, Heavy Chain
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D003564 Cytidine Deaminase An enzyme that catalyzes the deamination of cytidine, forming uridine. EC 3.5.4.5. Cytidine Aminohydrolase,Aminohydrolase, Cytidine,Deaminase, Cytidine
D000077329 Agammaglobulinaemia Tyrosine Kinase A non-receptor tyrosine kinase that is essential for the development, maturation, and signaling of B-LYMPHOCYTES. It contains an N-terminal zinc finger motif and localizes primarily to the PLASMA MEMBRANE and nucleus of B-lymphocytes. Mutations in the gene that encode this kinase are associated with X-LINKED AGAMMAGLOBULINEMIA. B Cell Progenitor Kinase,Bruton's Tyrosine Kinase,Bruton Tyrosine Kinase,Brutons Tyrosine Kinase,Kinase, Agammaglobulinaemia Tyrosine,Kinase, Bruton's Tyrosine,Tyrosine Kinase, Agammaglobulinaemia,Tyrosine Kinase, Bruton's

Related Publications

Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
October 1999, Genes & development,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
August 1998, Genes & development,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
July 2003, Molecular cell,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
March 2003, Ai zheng = Aizheng = Chinese journal of cancer,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
July 1998, Proceedings of the National Academy of Sciences of the United States of America,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
January 1999, The EMBO journal,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
November 2004, Molecular and cellular biology,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
April 2013, Cancer research,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
January 2013, PloS one,
Van B T Ta, and Marjolein J W de Bruijn, and Petra J ter Brugge, and Jan Piet van Hamburg, and Hans J A Diepstraten, and Pieter Fokko van Loo, and Rogier Kersseboom, and Rudi W Hendriks
November 2007, The Journal of biological chemistry,
Copied contents to your clipboard!